- Home
- News
- canada quebec
- microcatheter
Microcatheter Articles & Analysis
12 news found
The medical device industry is undergoing a transformative period marked by groundbreaking innovations and advanced materials. As healthcare continues to evolve, the need for devices that enhance patient outcomes while ensuring safety and reliability is more critical than ever. Among the various materials used in medical device design, polytetrafluoroethylene (PTFE tubing) has emerged as a ...
Instylla is now enrolling patients in a clinical trial for the world’s first hydrogel-based liquid embolic intended for the treatment of hypervascular tumors. A second initial application for its Embrace embolic therapy is hemorrhage control, where the product offers advantages in terms of simplicity, speed, and safety. Amar Sawhney and his teams, it seems, can make medical hydrogels do ...
Reflow Medical, Inc. announces that it has completed patient enrollment in the DEEPER OUS clinical trial (NCT03807531) for the company’s Temporary Spur Stent System, a novel device that features a retrievable stent designed for complex infrapopliteal disease. 106 patients have now been enrolled in the prospective, nonrandomized trial in multiple centers in Europe and New Zealand. Intended ...
Cerus Endovascular Ltd., a privately-held, commercial stage medical device company, today announced that it has received CE Mark approval for its state of the art CerusEndo MC 021 microcatheter, designed to allow physicians to access tortuous neurovasculature and deliver therapeutic devices to intended targets. “We remain committed to meeting the ever-increasing needs of the interventional ...
Balt (www.balt-corp.com) announced today it has received CE Mark Approval for its Silk Vista flow diverting stent to treat patients with unruptured intracranial aneurysms, enabling commercialization in over 30 countries in and around the European Union. Flow diverters are intended to divert blood flow away from an aneurysm, allowing the aneurysm to heal and reducing the risk of aneurysm rupture. ...
Cerus Endovascular Ltd., a privately held, commercial stage medical device company, today announced that it has received CE Mark approval for its 021 Contour Neurovascular System, compatible with smaller commercially available 021 microcatheters for the treatment of saccular intracranial aneurysms. The Contour Neurovascular System is a unique, fine mesh braid that is deployed across the neck of ...
Cerus Endovascular Ltd., a privatelyheld, commercial stage medical device company, today announced that it has received CE Mark approval for its Neqstent Coil Assisted Flow Diverter device, designed to treat intracranial aneurysms. Neqstent is designed to treat a range of aneurysm morphologies including wide-necked bifurcation and bifurcation aneurysms. Neqstent is an adjunctive intrasaccular ...
ALISO VIEJO, CA, March 5, 2020 — Okami Medical Inc., a medical device company, announced today the successful completion of the first cases with the LOBO™ Vascular Occlusion System. The first offering in the company’s product portfolio, LOBO-3, recently received 510(k) clearance from the U.S. Food and Drug Administration for the occlusion of peripheral arteries. The LOBO ...
Cerus Endovascular Ltd., a privately-held, commercial stage medical device company, today announced that it has now successfully completed its Series B financing having raised a total of $19.0 million from current and new institutional investors since commencement of the round in July 2018. The company also reported that it has received approval from the U.S. Food and Drug Administration (FDA) ...
Microcatheter-delivered device designed to provide rapid and focal occlusion of a wide range of peripheral arterial targets Aliso Viejo, CA – November 4, 2019 – Okami Medical Inc., a medical device company, today announced 510(k) clearance by the U.S. Food and Drug Administration (FDA) and initial launch of the LOBO™ Vascular Occlusion System. The Company further announced ...
Dr. Roberto Diletti from The Erasmus Center in Rotterdam, Netherlands, presented the results of the two-year follow-up analysis of the FFR-SEARCH observational registry during the EuroPCR conference in Paris. The analysis evaluated the outcomes of patients and prognostic value of post-percutaneous coronary intervention (post-PCI) FFR assessment, indicating patients with a lower FFR post-PCI ...
Infuseon Therapeutics’ novel central nervous system deliver device has received FDA 510(k) clearance as a therapeutic delivery device. Infuseon Therapeutics’ Cleveland Multiport CatheterTM (CMC), a multiport convection-enhanced delivery catheter, was designed by neurosurgeon Michael Vogelbaum, MD, PhD, from Cleveland Clinic’s Brain Tumor and NeuroOncology Center and Department ...